UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 4, 2016
NovoCure Limited
(Exact name of registrant as specified in its charter)
|
Jersey |
001-37565 |
98-1057807 |
|
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
|
Le Masurier House La Rue Le Masurier St. Helier, Jersey JE2 4YE (Address of Principal Executive Offices) |
|
|
|
|
|
|
Registrant’s telephone number, including area code: +44 (0)15 3475 6700 |
||
|
|
|
|
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. to Form 8-K):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders
NovoCure Limited (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”) on May 4, 2016. At the Annual Meeting, proxies and in-person shareholders representing 58,535,725 shares of the Company’s ordinary shares, or approximately 69.33% of the total shares entitled to vote, were present in person or by proxy and voted on the following two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the United States Securities and Exchange Commission on March 24, 2016.
1. Election of Directors. The nominees for election to the Company’s Board of Directors were elected as Class I directors to hold office until the Company’s 2019 Annual Meeting of Shareholders or until their successors are duly elected and qualified or until their offices are vacated, based upon the following votes:
|
|
For |
Against |
Withheld |
Broker non-votes |
|
William Burkoth |
56,273,503 |
¾ |
40,286 |
2,221,936 |
|
Yoram Palti |
56,196,153 |
¾ |
117,636 |
2,221,936 |
2. Ratification of Independent Registered Public Accounting Firm. The proposal to ratify the appointment, by the audit committee of the Company’s Board of Directors, of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global (“Kost Forer”), as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2016 was approved based upon the following votes:
|
For |
Against |
Abstain |
|
58,498,316 |
35,632 |
1,777 |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited
(Registrant)
Date: May 6, 2016
By: /s/ Wilhelmus Groenhuysen
Name: Wilhelmus Groenhuysen
Title: Chief Financial Officer